A parliamentary panel has pulled up the Department of Pharmaceuticals (DoP) for poor budgetary planning and dissatisfactory fund utilisation saying it has impacted efforts to provide affordable drugs and medical devices to the poor.
The Standing Committee on Chemicals and Fertilisers (2017-18) dealing with DoP also criticised drug pricing regulator NPPA for under-utilisation of allocated funds which could have affected the outreach of its e-initiates and other important functions.
In 2017-18, DoP was allocated Rs 247.74 crore at the budget estimate stage. It was increased to Rs 266.09 crore at the revised estimates stage, the committee said in its report.
"...but as on February 9, 2018, the actual expenditure of DoP has been only Rs 190.17 crore which is Rs 75.92 crore short of the allocated budget. This reflects on poor budgetary planning and dissatisfactory fund utilisation capacity of the DoP," it said.
It will also result in the lowering the pace of implementation of all crucial schemes like NIPERs, Jan Aushadhi scheme and assistance to PSUs, the report added.
"This also further contradicts the fund constraint argument given by the department while explaining their inability to to fulfil their physical targets under various schemes pending for want of sufficient funds," it said.
Poor budgetary planning and delays in utilisation of funds has not only affected department's budgetary performance but has also impacted its "noble mandate" of providing affordable drugs and medical devices to the poor people of the country, it noted.
"The committee therefore strongly recommend the department to stress upon scientific budgetary planning, effectively utilise allocated funds in time bound manner..," the report said.
While pulling up the NPPA for under utilisation of allocated funds, the committee asked the autonomous body to take "sincere steps to optimally utilised the allocated funds".
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
